pcn poster

Posters

Evaluation of Addiction Medicine Intensive Outpatient/Partial Hospitalization Program (AMIOP/PHP) at Fort Bliss, TX

Purpose: There are currently no standardized evaluations of longitudinal outcomes for Addiction Medicine Intensive Outpatient Programs (AMIOPs) in the military. At William Beaumont Army M...

Gisela Carter , LCSW;

11/22/2019

Assessing the Quality and Conformity of Mental Status Exam Descriptors

The mental status examination (MSE) is the objective portion of the psychiatric examination. Despite this, a lack of uniformity in the MSE has contributed to variability and as a result p...

Sarah Siddiqui , DO;

Erin Baker , PhD;

Gina Penley ;

Suzanna Freerksen , MD, FAPA;

Harold Veits , MD, DFAAPA;

11/22/2019

Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

Background: A combination of olanzapine and samidorphan (OLZ/SAM) is in development for schizophrenia to provide the efficacy of olanzapine while mitigating olanzapine-associated weight g...

Mark Namchuck , PhD;

John Newcomer , MD;

David McDonnell , MD;

Ying Jiang , PhD;

Christine Graham , PhD;

Linda Morrow , MD;

Carine Beysen , DPhil;

Frederico Toledo , MD;

Daiva Bajorunas , MD;

Bernard Silverman , MD;

11/22/2019

Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents With Schizophrenia: Post-hoc Analysis of a Two Year, Open-label Study

Background: Few studies have prospectively evaluated short- or long-term antipsychotic efficacy in treatment-naïve (vs. previously treated) first-episode schizophrenia. The aim of this po...

Robert Goldman , PhD;

Christoph U. Correll , MD;

Michael Tocco , PhD;

Jay Hsu , PhD;

11/22/2019

Effect of Dasotraline on Body Weight in Patients With Binge-Eating Disorder

Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated significant efficacy in treatment of binge-eating disorder (BED). We n...

Leslie Citrome , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Todd Grinnell , BA;

Andrei Pikalov , MD, PhD;

Joyce Tsai , PhD;

11/22/2019

Efficacy (NNT) and Tolerability (NNH) of Cariprazine in Bipolar Disorder

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

Leslie Citrome , MD;

11/22/2019

Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants With Narcolepsy or Obstructive Sleep Apnea With a History of Depression

Background: Depression is commonly comorbid with narcolepsy and obstructive sleep apnea (OSA). Solriamfetol (SunosiTM), a dopamine/norepinephrine reuptake inhibitor, has been approved in ...

Lawrence Lee , PhD;

Russell 1022962 , PhD;

Atul Malhotra , MD;

Paula Schweitzer , MD, PhD;

Kimberly Babson , PhD;

Shay Bujanover , MD;

Kingman Strohl , MD;

Ruth Benca , MD, PhD;

11/22/2019

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019

Trauma-Informed Care in the Middle East

Introduction: The problem of increased level and severity of stress as a result of regional and international conflicts is not paralleled by an adequate level of knowledge and preparednes...

11/22/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products